VOYA INVESTMENT MANAGEMENT LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 137 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2019. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.

Quarter-by-quarter ownership
VOYA INVESTMENT MANAGEMENT LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$7,633,633
-17.3%
146,547
+0.6%
0.01%
-9.1%
Q2 2023$9,227,877
+25.0%
145,734
+6.9%
0.01%
+10.0%
Q1 2023$7,379,942
+2.3%
136,287
-0.0%
0.01%0.0%
Q4 2022$7,213,525
+14.8%
136,310
+0.9%
0.01%
+11.1%
Q3 2022$6,286,296
-9.7%
135,102
+10.7%
0.01%
-50.0%
Q2 2022$6,965,000
+7.6%
122,010
+15.3%
0.02%
+38.5%
Q1 2022$6,472,000
+344.5%
105,782
+280.3%
0.01%
+333.3%
Q4 2021$1,456,000
+40.4%
27,819
+0.0%
0.00%
+50.0%
Q3 2021$1,037,000
-8.6%
27,8060.0%0.00%0.0%
Q2 2021$1,135,000
+14.0%
27,806
-5.3%
0.00%0.0%
Q1 2021$996,000
+10.2%
29,350
+3.2%
0.00%0.0%
Q4 2020$904,000
+61.1%
28,432
+30.1%
0.00%
+100.0%
Q3 2020$561,000
+13.3%
21,857
+13.3%
0.00%0.0%
Q2 2020$495,000
+24.7%
19,296
-25.4%
0.00%0.0%
Q1 2020$397,000
-47.8%
25,860
+16.8%
0.00%
-50.0%
Q4 2019$760,000
+420.5%
22,137
+13.7%
0.00%
Q3 2019$146,000
-42.3%
19,4780.0%0.00%
-100.0%
Q2 2019$253,000
+6.8%
19,4780.0%0.00%0.0%
Q1 2019$237,000
+6.8%
19,4780.0%0.00%0.0%
Q4 2018$222,000
-44.5%
19,478
+5.6%
0.00%0.0%
Q3 2018$400,000
+22.7%
18,4470.0%0.00%0.0%
Q2 2018$326,000
-14.2%
18,447
+2.1%
0.00%0.0%
Q1 2018$380,000
+45.0%
18,0660.0%0.00%0.0%
Q4 2017$262,000
-1.9%
18,066
+6.8%
0.00%0.0%
Q3 2017$267,000
+27.1%
16,9110.0%0.00%
Q2 2017$210,000
-11.4%
16,911
+16.0%
0.00%
-100.0%
Q1 2017$237,000
+7.7%
14,5730.0%0.00%0.0%
Q4 2016$220,000
-0.9%
14,5730.0%0.00%
Q3 2016$222,000
-60.8%
14,5730.0%0.00%
-100.0%
Q2 2016$566,000
+108.9%
14,573
+49.5%
0.00%0.0%
Q1 2016$271,000
-48.3%
9,7490.0%0.00%0.0%
Q4 2015$524,000
+34.4%
9,7490.0%0.00%0.0%
Q3 2015$390,000
-1.0%
9,749
-20.9%
0.00%0.0%
Q2 2015$394,000
+34.0%
12,3310.0%0.00%0.0%
Q1 2015$294,000
+34.9%
12,3310.0%0.00%
Q4 2014$218,000
+29.0%
12,3310.0%0.00%
Q3 2014$169,000
-18.8%
12,3310.0%0.00%
Q2 2014$208,00012,3310.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2019
NameSharesValueWeighting ↓
Sarissa Capital Management LP 640,000$25,626,0006.33%
Redmile Group, LLC 1,322,592$52,957,0004.01%
SENZAR ASSET MANAGEMENT, LLC 556,224$22,271,209,0003.24%
RA Capital Management 314,349$12,587,0001.81%
WALL STREET ASSOCIATES 205,657$8,235,0001.58%
Parametrica Management Ltd 5,400$216,0001.36%
Rhenman & Partners Asset Management AB 165,000$6,607,0001.05%
EAM Investors, LLC 95,168$3,811,0000.60%
Rock Springs Capital Management LP 180,000$7,207,0000.58%
WASATCH ADVISORS LP 1,085,973$43,482,0000.58%
View complete list of INTRA CELLULAR THERAPIES INC shareholders